NDA 19-758/SLR-044

Novartis
Attention: James T. Rawls, Pharm.D.
Assistant Director, Drug Regulatory Affairs
59 Route 10
East Hanover, NJ 07936

29 AUG 2001

Dear Dr. Rawls:

Please refer to your supplemental new drug application dated April 13, 2001, received April 18, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Clozaril (clozapine) tablets.

We acknowledge receipt of your submission dated July 24, 2001. Your submission of July 24, 2001 constituted a complete response to our June 8, 2001 action letter.

This "Changes Being Effected" supplemental new drug application provides for the labeling changes requested in our letter of September 25, 2000, specifically modification of labeling text to more clearly state that these agents are indicated for the treatment of schizophrenia. Additional changes have been effected in the following sections of labeling:

- CONTRAINDICATIONS
- PRECAUTIONS: Anticholinergic Toxicity and Drug Interactions
- ADVERSE REACTIONS: Postmarketing Clinical Experience
- DOSAGE AND ADMINISTRATION: Therapeutic Dose Adjustment and Discontinuation of Treatment

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 19-758/SLR-044." Approval of this submission by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Steven D. Hardeman, R.Ph., Senior Regulatory Project Manager, at (301) 594-5525.

Sincerely,

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research